title: Bone marrow transplantation (BMT) for thalassemia major (TM). The French experience.
authors.affiliation: Pediatrie A, hopital nord, Saint Etienne, France.
authors.forename: D
authors.initials: D
authors.lastname: Frappaz
authors.forename: E
authors.initials: E
authors.lastname: Gluckman
authors.forename: G
authors.initials: G
authors.lastname: Souillet
authors.forename: D
authors.initials: D
authors.lastname: Maraninchi
authors.forename: F
authors.initials: F
authors.lastname: Demeocq
authors.forename: A
authors.initials: A
authors.lastname: Fischer
authors.forename: P
authors.initials: P
authors.lastname: Lutz
authors.forename: J P
authors.initials: JP
authors.lastname: Bergerat
authors.forename: P
authors.initials: P
authors.lastname: Hervé
authors.forename: F
authors.initials: F
authors.lastname: Freycon
mesh_terms: D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D005602:France; D006084:Graft Rejection; D006086:Graft vs Host Disease / Q000517:prevention & control; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D013789:Thalassemia / Q000628:therapy*
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D002066:Busulfan